Insider share sale at Acumen (NASDAQ: ABOS) filed under Rule 144

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider plans to sell 5,805 common shares under Rule 144. The shares are to be sold through Merrill Lynch, with an aggregate market value of $11,565.85, on or about January 7, 2026 on the NASDAQ exchange. The filing shows these shares relate to the vesting of restricted stock unit awards of 4,105 shares on January 2, 2026 and 1,700 shares on January 6, 2026, granted as part of the issuer’s equity compensation plan. The notice also reports that Matt Zuga sold 4,000 common shares for $7,842.33 on January 5, 2026 and 5,100 shares for $10,027.50 on January 6, 2026. Common shares outstanding are listed as 60,573,425.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	5805	11565.85	60573425	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/02/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			4105	01/02/2026	Granted as part of issuer equity compensation plan
Common stock	01/06/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			1700	01/06/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7842.33
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	5100	10027.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ABOS Form 144 filing disclose?

The Form 144 notice discloses an intended sale of 5,805 shares of Acumen Pharmaceuticals common stock under Rule 144, to be executed through Merrill Lynch on or about January 7, 2026 on the NASDAQ exchange.

How many Acumen Pharmaceuticals (ABOS) shares are involved in the planned sale?

The filing lists 5,805 common shares to be sold, with an aggregate market value of $11,565.85.

How were the ABOS shares being sold under Form 144 acquired?

The shares were acquired through vesting of restricted stock unit awards from Acumen Pharmaceuticals: 4,105 shares vested on January 2, 2026 and 1,700 shares vested on January 6, 2026, granted as part of the issuer’s equity compensation plan.

What prior ABOS stock sales are reported in the last 3 months?

The notice states that Matt Zuga sold Acumen Pharmaceuticals common stock of 4,000 shares for $7,842.33 on January 5, 2026 and 5,100 shares for $10,027.50 on January 6, 2026.

How many Acumen Pharmaceuticals (ABOS) shares are outstanding in this Form 144?

The Form 144 lists 60,573,425 common shares of Acumen Pharmaceuticals as outstanding.

On which exchange will the ABOS shares in this Form 144 be sold?

The filing indicates that the 5,805 Acumen Pharmaceuticals common shares are expected to be sold on the NASDAQ exchange.